最近审阅: 26 十月 2020
最近更新: 12 十月 2017

小结

定义

病史和体格检查

关键诊断因素

  • 慢性心境障碍需持续超过 2 年
  • 抑郁症状出现在大多数日子里每一天的大多数时间
  • 在过去 2 年(儿童或青少年为 1 年)没有出现过一段时间的情绪高涨
  • 重性抑郁的症状可能持续出现 2 年或更长的时间

其他诊断因素

  • 没有躁狂/轻症躁狂或精神分裂症的症状
  • 不存在可能引起心境障碍的躯体疾病、药物使用或物质滥用
  • 疲劳或精力不足
  • 自尊心低
  • 注意力不集中
  • 感到无望
  • 体重改变
  • 睡眠障碍

危险因素

  • 阳性家族史
  • 女性

诊断性检查

首要检查

  • 患者健康问卷-9 (PHQ-9)
  • Beck抑郁量表 (BDI)
  • 抑郁症状快速清单 (QIDS)
更多 首要检查

治疗流程

急性处理

撰稿人

David J. Hellerstein

Professor of Clinical Psychiatry

Columbia University Medical Center

Director, Depression Evaluation Service

New York State Psychiatric Institute

New York

NY

利益声明

DJH has received grant support from Eli Lilly, Pfizer, Forest Pharmaceuticals, GlaxoSmithKline, and Bristol-Myers Squibb. He is a board member for the nonprofit organization Mood Disorders Support Group. He is author of a number of references cited in this monograph.

Dr David J. Hellerstein would like to gratefully acknowledge Dr David L. Dunner, a previous contributor to this monograph. DLD has received grant support from Cyberonics. DLD has received fees for consulting from: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka, Healthcare Technology Sys, Jazz Pharma, Sanofi-Aventis, and MedAvante. DLD is on the Speaker's Bureau for: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharma, Neuronetics, and Astra-Zeneca. DLD is an author of several references cited in this monograph.

同行评议者展开全部内容

Professor of Psychiatry and Mental Health

National Coordinator of the OSPI-Europe and EAAD projects

Mental Health Department of the Faculty of Medical Sciences

New University of Lisbon (UNL)

Lisbon

Portugal

利益声明

RG has been paid by Bristol-Myers Squibb for being on the advisory board.

Assistant Professor

Columbia University College of Physicians & Surgeons

New York

NY

利益声明

SS declares that he has no competing interests.

内容使用需遵循免责声明